Medindia

X

Dr. Nicholas Medendorp, Jr. Named CEO of PhotonMD, Inc.

Thursday, March 9, 2017 General News J E 4
Advertisement
Medical Device Business is Second Portfolio Company of KNOW Bio, LLC

DURHAM, N.C., March 9, 2017 /PRNewswire/ -- KNOW Bio, LLC., a leading innovator in healthcare, today announced the debut of PhotonMD, Inc., their new medical device business. It is led by Dr. Nicholas Medendorp, Jr, who serves as President and Chief Executive Officer.

Medendorp, founder of PhotonMD, is a seasoned technology and product development leader with more than 80 US patents in LED and lighting products. He has more than 19 years of experience in the technology development industry and has served in a broad range of functions, including electro-optics, product development, manufacturing and marketing. In addition, he has extensive experience in developing companies to high growth and profitability, including senior leadership roles with start-ups and large technology companies.

"We started PhotonMD with one simple goal: to improve peoples' lives using tailored photomedicine products. And to that end, we are focused on the development of medical devices that target therapeutic solutions for aesthetic applications, chronic inflammatory diseases, and other conditions susceptible to light-based healing," said Dr. Medendorp.

"Nick Medendorp brings a very diverse technology knowledge base and is highly skilled at building strong teams.  Nick's passion and tenacity are positioning PhotonMD as a dominant player in the photomedicine device market," said Neal Hunter, Chairman of KNOW Bio, LLC.

Most recently, Medendorp served as Vice President, Medical Devices at Novan, Inc (NASDAQ: NOVN) where he led the team responsible for the creation and development of medical devices.  This group, which was the foundation for PhotonMD, was included in the separation of assets in late 2015 prior to Novan taking the medical dermatology business public.  Previously, Nick served as Vice President of Research and Development and Vice President of Operations at Cree, Inc. where he focused on building teams that accelerated LED technology development and deployment in commercial and industrial applications. He earned a B.S., M.S. and Ph.D. in Materials Engineering from Purdue University.

"I am proud of the world class team we have assembled that has more than 65 years of product development experience, medical device commercialization, and has been involved in more than 50 device clearances. I look forward to our team accelerating recent advancements in the understanding of the biological responses to light and improvements in the digitization and selectivity of light-based technologies," Medendorp said.

About PhotonMDPhotonMD's Modulated Light Therapy (MLTTM) technology is based on a photomedicine platform that can be delivered in a variety of doses and tailored form factors for specific indications. KNOW Bio, LLC was created to develop and optimize biotechnology solutions for many different applications. For more information, please visit www.photonmd.com.

Forward-looking StatementsExcept for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device and drug development processes; competition; and other risks described in other Company press releases and presentations. KNOW Bio and PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.

ContactRay Young: ray@razorsharppr.com T: (512) 633-6855

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-nicholas-medendorp-jr-named-ceo-of-photonmd-inc-300421133.html

SOURCE KNOW Bio, LLC

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The Amyloidosis Research Consortium, In Partnershi...
S
The Evolving Legal Cannabis Market